Tesofensine Side Effects: Safety Signals and Warnings
Tesofensine safety concerns are compound-specific. The main listed side effects are Dry mouth, Insomnia, and Constipation. The main warning signals are Significant cardiovascular concerns - increased heart rate and blood pressure, Not yet approved in any jurisdiction, and Contraindicated in uncontrolled hypertension.
Direct Answer
Tesofensine completed a Phase 2b trial showing 10.6% weight loss at 0.5mg over 24 weeks - a clinically meaningful result that outperforms most non-GLP-1 agents. The triple monoamine reuptake inhibition mechanism is distinct from incretin-based approaches, making it relevant for patients who respond poorly to GLP-1 agonists. Phase 3 completion is the outstanding question, but the Phase 2b signal is genuine.
- Evidence grade
- Level B
- Research status
- Phase 3
- Category
- Weight Loss & Metabolic
- Best for
- Non-GLP-1 weight loss research, monoamine reuptake inhibition pharmacology, obesity treatment alternatives
Reported Side Effects
- Dry mouth
- Insomnia
- Constipation
- Increased heart rate
- Elevated blood pressure
- Nausea
- Diarrhea
- Headache
Warnings
- Significant cardiovascular concerns - increased heart rate and blood pressure
- Not yet approved in any jurisdiction
- Contraindicated in uncontrolled hypertension
- Potential for abuse given dopaminergic activity - though clinical data suggest low abuse potential
- Should not be combined with MAO inhibitors
- Extremely long half-life means adverse effects persist for extended periods after discontinuation
Known or Plausible Interactions
- MAO inhibitors (contraindicated - risk of serotonin syndrome and hypertensive crisis)
- SSRIs and SNRIs (increased serotonergic effects)
- Sympathomimetics (additive cardiovascular effects)
- CYP3A4 inhibitors (may increase tesofensine levels)
Regulatory Context
Not approved in any jurisdiction. Phase 3 clinical trials ongoing. Not a controlled substance.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 3 |
| Best supported outcomes | Body Weight Reduction (Level B), Appetite Suppression (Level B), and Cardiovascular Effects (Level B) |
| Primary citation count | 2 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Tesofensine Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/tesofensine-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.